Meeting
2022 ASCO Annual Meeting
Neoadjuvant nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) versus chemo for resectable (IB–IIIA) non-small cell lung cancer (NSCLC): Association of pathological regression with event-free survival (EFS) in CheckMate 816.
Authors
Mariano Provencio-Pulla
Hospital Universitario Puerta de Hierro, Madrid, Spain
Mariano Provencio-Pulla , Jonathan Spicer , Janis M. Taube , Claudio Martin , David R. Spigel , Changli Wang , Nicolas Girard , Shun Lu , Tetsuya Mitsudomi , Mark M. Awad , Enriqueta Felip , Julie R. Brahmer , Stephen Broderick , Scott Swanson , Keith Kerr , Li Li , Junliang Cai , Judith Bushong , Phuong Tran , Patrick M. Forde
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Local-Regional Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT02998528
Citation
J Clin Oncol 40, 2022 (suppl 17; abstr LBA8511)
DOI
10.1200/JCO.2022.40.17_suppl.LBA8511
Abstract #
LBA8511
Poster Bd #
138
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Checkmate 816: A phase 3, randomized, open-label trial of nivolumab plus ipilimumab vs platinum-doublet chemotherapy as neoadjuvant treatment for early-stage NSCLC.
First Author: Patrick M. Forde
Poster
2023 ASCO Annual Meeting
Response to neoadjuvant immune checkpoint inhibitor (ICI)-based therapy in oncogene-driven resectable non-small cell lung cancer (NSCLC).
First Author: Samuel Rosner
Poster
2022 ASCO Annual Meeting
Neoadjuvant nivolumab in early-stage non–small cell lung cancer (NSCLC): Five-year outcomes.
First Author: Samuel Rosner
Poster
2022 ASCO Annual Meeting
Multimodal prediction of response to neoadjuvant nivolumab and chemotherapy for surgically resectable stage IIIA non–small cell lung cancer.
First Author: Loïc Ferrer